Raymond James Financial Inc. Makes New $10.81 Million Investment in Envista Holdings Co. (NYSE:NVST)

Raymond James Financial Inc. purchased a new stake in Envista Holdings Co. (NYSE:NVST) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 560,265 shares of the company’s stock, valued at approximately $10,808,000.

Several other institutional investors have also modified their holdings of the business. Franklin Resources Inc. boosted its holdings in Envista by 26.5% in the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after purchasing an additional 830,861 shares during the period. Pacer Advisors Inc. raised its position in Envista by 22.2% in the 3rd quarter. Pacer Advisors Inc. now owns 3,529,827 shares of the company’s stock valued at $69,749,000 after purchasing an additional 642,401 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Envista by 2.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company’s stock valued at $57,233,000 after buying an additional 71,435 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Envista by 8.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,317,631 shares of the company’s stock valued at $44,707,000 after buying an additional 179,600 shares during the period. Finally, Iron Triangle Partners LP acquired a new position in shares of Envista during the third quarter worth about $43,262,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Jefferies Financial Group lifted their price target on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research note on Thursday, January 23rd. Needham & Company LLC restated a “hold” rating on shares of Envista in a research note on Thursday, March 6th. Morgan Stanley dropped their price objective on Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. New Street Research set a $19.00 target price on Envista in a research note on Thursday, March 6th. Finally, Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target for the company. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Envista currently has a consensus rating of “Hold” and a consensus price target of $20.18.

Envista Stock Down 0.8 %

NVST stock opened at $16.87 on Friday. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $23.00. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -2.60, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. The company has a fifty day moving average price of $19.80 and a 200 day moving average price of $19.59.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Sell-side analysts expect that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.